Quiver Bioscience logo — Decoding Brain Disease to Reimagine Drug Development

Quiver Bioscience

Decoding Brain Disease to Reimagine Drug Development

Founded 2013 United States Cambridge, United States 47 employees Acquired Total: $20.48M Biotechnology

General Information

Company Name Quiver Bioscience
Founded Year 2013
Location United States Cambridge, United States
Employees 47
Industries Biotechnology
Funding Stage Acquired
Business Model Platform, B2B, SaaS
Revenue Model Licensing, Subscription, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Quiver Bioscience. To contact Quiver Bioscience, visit quiverbioscience.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Quiver Bioscience compare?

A PDF of Quiver Bioscience and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Quiver Bioscience soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Quiver Bioscience

Quiver Bioscience is a pioneering biotechnology company founded in 2013 with a mission encapsulated by their slogan: "Decoding Brain Disease to Reimagine Drug Development." The company is at the forefront of developing transformational medicines for brain disorders, leveraging cutting-edge technologies.

Quiver's innovation lies in its creation of the "Genomic Positioning System," the world's most comprehensive neuronal insight map, constructed using advanced single cell imaging, multi-omics, and proprietary AI/ML approaches. This technology enables the discovery of new biology and effective drug targets, potentially revolutionizing drug development for neurological diseases.

Recently, Quiver secured a $1.99M grant investment from the National Institute of Neurological Disorders and Stroke, highlighting investor confidence in their novel approach and promising solutions. This signals robust momentum in their quest to advance understanding and treatment of brain diseases.

Business keywords: Precision Medicine, Genomics, Neurology, Drug Discovery, Personalized Medicine, Genetic Therapies, Optical Electrophysiology, Gene Editing, Stem Cells, Optogenetics, Transcriptomics, Functional Genomics, Neurodegenerative Diseases, Therapeutic Design & Screening

Services & Products

AI-powered therapeutic development
High-dimensional data analysis
Target identification and validation
Translational research

Target Customers

pharmaceutical companies biotech enterprises neurological disease researchers healthcare providers focused on CNS disorders

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $1.99M 1
National Institute of Neurological Disorders and Stroke
01 May 2026
Grant $2.15M 1
National Institute of Neurological Disorders and Stroke
01 Jul 2025
Acquisition Undisclosed 1
Expon Capital
01 Jul 2023
Grant $1.30M 1
National Institute of Health
01 Jan 2021
Grant $760.00K 2
National Institute of Health, US Department of Health and Human Services
01 Jan 2020
Grant $7.90M 2
National Institute of Health, US Department of Health and Human Services
01 Jan 2019
Grant $520.00K 2
National Institute of Health, US Department of Health and Human Services
01 Jan 2018
Grant $2.39M 2
National Institute of Health, US Department of Health and Human Services
01 Jan 2017
Grant $1.97M 2
National Institute of Health, US Department of Health and Human Services
01 Jan 2016
Grant $820.00K 2
National Institute of Health, US Department of Health and Human Services
01 Jan 2015

View All 11 Funding Rounds

Quiver Bioscience Alternatives & Competitors

View All Alternatives
Quiver Bioscience vs

Medicines to keep you biologically young by targeting the pathological cells that drive chronic dise...

Series A
32 employees
Biotechnology, Health Care
Quiver Bioscience vs

Creating breakthrough innovative therapeutics for serious CNS disorders

Series C
144 employees
Biopharma, Biotechnology
Quiver Bioscience vs
Function
Function United States

Personalized functional genomics transforming the future of cancer

Series A
7 employees
Biotechnology, Health and Wellness

FAQ About Quiver Bioscience

Decoding Brain Disease to Reimagine Drug Development
Quiver Bioscience was founded in 2013.
Quiver Bioscience is headquartered in Cambridge, United States.
Quiver Bioscience operates in Biotechnology. Its work centres on Precision Medicine, Genomics, Neurology and Drug Discovery. Its customers include pharmaceutical companies, biotech enterprises and neurological disease researchers.
Quiver Bioscience has a Platform, B2B and SaaS business model. Its revenue comes from Licensing, Subscription and Service Fee.
Quiver Bioscience has approximately 47 employees.
Quiver Bioscience has completed 11 funding rounds, raising a total of $20.48M. The latest funding stage is Acquired.
Quiver Bioscience offers: AI-powered therapeutic development, High-dimensional data analysis, Target identification and validation, Translational research.
Top alternatives and competitors to Quiver Bioscience include Rubedo Life Sciences, MapLight Therapeutics, Inc., Function, Locanabio, Inc., Editas Medicine. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Quiver Bioscience and Rubedo Life Sciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Quiver Bioscience, https://bouncewatch.com/company/quiver-bioscience, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes